Marshall Wace’s AnaptysBio ANAB Stock Holding History

Marshall Wace’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.96M	Sell	43,822 -24,225	-36%	-$1.47M	﹤0.01%	1636
2026 Q1	$3.77M	Buy	+68,047	New	+$3.66M	﹤0.01%	1439
2025 Q4	–	Sell	-54,416	Closed	-$1.67M	–	2927
2025 Q3	$1.67M	Buy	+54,416	New	+$1.25M	﹤0.01%	1708
2025 Q2	–	Sell	-92,870	Closed	-$1.73M	–	2672
2025 Q1	$1.73M	Buy	+92,870	New	+$1.55M	﹤0.01%	1533
2024 Q4	–	Sell	-8,978	Closed	-$301K	–	2554
2024 Q3	$301K	Buy	+8,978	New	+$307K	﹤0.01%	2143
2024 Q1	–	Sell	-33,357	Closed	-$715K	–	2409
2023 Q4	$715K	Sell	33,357 -1,520	-4%	-$26.2K	﹤0.01%	1592
2023 Q3	$626K	Buy	34,877 +21,576	+162%	+$412K	﹤0.01%	1650
2023 Q2	$271K	Sell	13,301 -11,096	-45%	-$225K	﹤0.01%	2170
2023 Q1	$531K	Buy	+24,397	New	+$593K	﹤0.01%	2076
2018 Q4	–	Sell	-108,870	Closed	-$10.9M	–	1570
2018 Q3	$10.9M	Buy	+108,870	New	+$9.03M	0.09%	287
2018 Q2	–	Sell	-6,969	Closed	-$725K	–	696
2018 Q1	$725K	Buy	+6,969	New	+$785K	0.03%	294

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Marshall Wace's ANAB Position: Q2 2026 in Review

Marshall Wace reduced its AnaptysBio (ANAB) stake by 36% in Q2 2026, selling an estimated $1.47M and leaving 43,822 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Marshall Wace first reported a position in ANAB in Q1 2018 and has held it in 11 quarters since. The position peaked at $10.9M in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Marshall Wace held 43,822 shares of AnaptysBio worth $2.96M as of Q2 2026.
Marshall Wace sold 24,225 AnaptysBio shares in Q2 2026, an estimated $1.47M.
AnaptysBio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1636 holding.
Marshall Wace first reported a position in AnaptysBio in Q1 2018 and has held it in 11 quarters since.
Marshall Wace's AnaptysBio position peaked at $10.9M in Q3 2018.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.